B. Riley Wealth Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

B. Riley Wealth Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-754	Closed	-$124	–	1293
2014 Q4	$124	Buy	+754	New	+$125K	﹤0.01%	1603
2014 Q3	–	Sell	-772	Closed	-$113K	–	1288
2014 Q2	$113K	Buy	+772	New	+$107K	0.03%	662

Other funds holding JAZZ

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

WBC

Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

B. Riley Wealth Advisors's JAZZ Position: Q1 2015 in Review

B. Riley Wealth Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2015, closing a stake of 754 shares — an estimated $124 sold.

B. Riley Wealth Advisors first reported a position in JAZZ in Q2 2014 and held it in 2 quarters. The position peaked at $113K in Q2 2014. 354 funds tracked by Wall St. Rank hold JAZZ as of Q1 2015.

B. Riley Wealth Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
B. Riley Wealth Advisors sold 754 Jazz Pharmaceuticals shares in Q1 2015, an estimated $124.
B. Riley Wealth Advisors first reported a position in Jazz Pharmaceuticals in Q2 2014 and held it in 2 quarters.
B. Riley Wealth Advisors's Jazz Pharmaceuticals position peaked at $113K in Q2 2014.
354 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2015.

Based on B. Riley Wealth Advisors's 13F filing for Q1 2015, filed 14 May 2015.